IP Library › Granted Patent US 11,248,046
Granted Patent B2
US 11,248,046 · App. 16/790,066 · Granted Feb 15, 2022

Claudin 6 antibodies and uses thereof

Inventors: Ross Chambers (Philadelphia, PA); Joseph Rucker (Philadelphia, PA); Thomas Charpentier (Philadelphia, PA); Lewis J. Stafford (Philadelphia, PA); Brad Screnci (Philadelphia, PA); Trevor Barnes (Philadelphia, PA); Benjamin Doranz (Philadelphia, PA)
Assignee: Integral Molecular, Inc.
C07K16/28A61K47/6849C07K2317/31C07K2317/565C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,248,046
App. No.
16/790,066
Granted
Feb 15, 2022
Kind
B2
Abstract

Antibodies and compositions against Claudin 6 and uses thereof are provided.

Claims (110)

1. An antibody comprising a heavy chain variable region comprising a heavy chain CDR1 (HCDR1), CDR2 (HCDR2), and CDR3 (HCDR3), and a light chain variable region comprising a light chain CDR1 (LCDR1), CDR2 (LCDR2), and CDR3 (LCDR3), and wherein the antibody has:

a HCDR1 of SEQ ID NO: 139, HCDR2 of SEQ ID NO: 140, and HCDR3 of SEQ ID NO:

82, a LCDR1 of SEQ ID NO: 83; a LCDR2 of SEQ ID NO: 84; and a LCDR3 of SEQ ID NO: 85;

a HCDR1 of SEQ ID NO: 141, HCDR2 of SEQ ID NO: 142, and HCDR3 of SEQ ID NO: 57, a LCDR1 of SEQ ID NO: 87; a LCDR2 of SEQ ID NO: 88; and a LCDR3 of SEQ ID NO: 89;

a HCDR1 of SEQ ID NO: 143, HCDR2 of SEQ ID NO: 144, and HCDR3 of SEQ ID NO: 92, a LCDR1 of SEQ ID NO: 93; a LCDR2 of SEQ ID NO: 88; and a LCDR3 of SEQ ID NO: 94;

a HCDR1 of SEQ ID NO: 145, HCDR2 of SEQ ID NO: 146, and HCDR3 of SEQ ID NO: 97, a LCDR1 of SEQ ID NO: 98; a LCDR2 of SEQ ID NO: 99; and a LCDR3 of SEQ ID NO: 100;

a HCDR1 of SEQ ID NO: 25, HCDR2 of SEQ ID NO: 26, and HCDR3 of SEQ ID NO: 27, a LCDR1 of SEQ ID NO: 22; a LCDR2 of SEQ ID NO: 23; and a LCDR3 of SEQ ID NO: 24;

a HCDR1 of SEQ ID NO: 31, HCDR2 of SEQ ID NO: 32, and HCDR3 of SEQ ID NO: 33, a LCDR1 of SEQ ID NO: 28; a LCDR2 of SEQ ID NO: 29; and a LCDR3 of SEQ ID NO: 30;

a HCDR1 of SEQ ID NO: 37, HCDR2 of SEQ ID NO: 38, and HCDR3 of SEQ ID NO: 39, a LCDR1 of SEQ ID NO: 34; a LCDR2 of SEQ ID NO: 29; and a LCDR3 of SEQ ID NO: 36;

a HCDR1 of SEQ ID NO: 43, HCDR2 of SEQ ID NO: 44, and HCDR3 of SEQ ID NO: 45, a LCDR1 of SEQ ID NO: 40; a LCDR2 of SEQ ID NO: 41; and a LCDR3 of SEQ ID NO: 43;

a HCDR1 of SEQ ID NO: 25, HCDR2 of SEQ ID NO: 26, and HCDR3 of SEQ ID NO: 27, a LCDR1 of SEQ ID NO: 22; a LCDR2 of SEQ ID NO: 23; and a LCDR3 of SEQ ID NO: 24;

a HCDR1 of SEQ ID NO: 31, HCDR2 of SEQ ID NO: 46, and HCDR3 of SEQ ID NO: 33, a LCDR1 of SEQ ID NO: 28; a LCDR2 of SEQ ID NO: 29; and a LCDR3 of SEQ ID NO: 30;

a HCDR1 of SEQ ID NO: 37, HCDR2 of SEQ ID NO: 48, and HCDR3 of SEQ ID NO: 39, a LCDR1 of SEQ ID NO: 47; a LCDR2 of SEQ ID NO: 29; and a LCDR3 of SEQ ID NO: 36;

a HCDR1 of SEQ ID NO: 43, HCDR2 of SEQ ID NO: 49, and HCDR3 of SEQ ID NO: 45, a LCDR1 of SEQ ID NO: 40; a LCDR2 of SEQ ID NO: 41; and a LCDR3 of SEQ ID NO: 42;

a HCDR1 of SEQ ID NO: 53, HCDR2 of SEQ ID NO: 54, and HCDR3 of SEQ ID NO: 33, a LCDR1 of SEQ ID NO: 50; a LCDR2 of SEQ ID NO: 51; and a LCDR3 of SEQ ID NO: 52;

a HCDR1 of SEQ ID NO: 55, HCDR2 of SEQ ID NO: 54, and HCDR3 of SEQ ID NO: 33, a LCDR1 of SEQ ID NO: 50; a LCDR2 of SEQ ID NO: 51; and a LCDR3 of SEQ ID NO: 52;

a HCDR1 of SEQ ID NO: 56, HCDR2 of SEQ ID NO: 101, and HCDR3 of SEQ ID NO: 57, a LCDR1 of SEQ ID NO: 58; a LCDR2 of SEQ ID NO: 59; and a LCDR3 of SEQ ID NO: 60;

a HCDR1 of SEQ ID NO: 56, HCDR2 of SEQ ID NO: 101, and HCDR3 of SEQ ID NO: 61, a LCDR1 of SEQ ID NO: 58; a LCDR2 of SEQ ID NO: 59; and a LCDR3 of SEQ ID NO: 60;

a HCDR1 of SEQ ID NO: 62, HCDR2 of SEQ ID NO: 101, and HCDR3 of SEQ ID NO: 63, a LCDR1 of SEQ ID NO: 64; a LCDR2 of SEQ ID NO: 59; and a LCDR3 of SEQ ID NO: 60;

a HCDR1 of SEQ ID NO: 62, HCDR2 of SEQ ID NO: 101, and HCDR3 of SEQ ID NO: 65, a LCDR1 of SEQ ID NO: 64; a LCDR2 of SEQ ID NO: 59; and a LCDR3 of SEQ ID NO: 60;

a HCDR1 of SEQ ID NO: 62, HCDR2 of SEQ ID NO: 101, and HCDR3 of SEQ ID NO: 66, a LCDR1 of SEQ ID NO: 64; a LCDR2 of SEQ ID NO: 59; and a LCDR3 of SEQ ID NO: 60;

a HCDR1 of SEQ ID NO: 62, HCDR2 of SEQ ID NO: 101, and HCDR3 of SEQ ID NO: 67, a LCDR1 of SEQ ID NO: 64; a LCDR2 of SEQ ID NO: 59; and a LCDR3 of SEQ ID NO: 60;

a HCDR1 of SEQ ID NO: 62, HCDR2 of SEQ ID NO: 101, and HCDR3 of SEQ ID NO: 65, a LCDR1 of SEQ ID NO: 58; a LCDR2 of SEQ ID NO: 68; and a LCDR3 of SEQ ID NO: 60;

a HCDR1 of SEQ ID NO: 62, HCDR2 of SEQ ID NO: 101, and HCDR3 of SEQ ID NO: 126, a LCDR1 of SEQ ID NO: 58; a LCDR2 of SEQ ID NO: 68; and a LCDR3 of SEQ ID NO: 60;

a HCDR1 of SEQ ID NO: 62, HCDR2 of SEQ ID NO: 101, and HCDR3 of SEQ ID NO: 69, a LCDR1 of SEQ ID NO: 58; a LCDR2 of SEQ ID NO: 68; and a LCDR3 of SEQ ID NO: 60;

a HCDR1 of SEQ ID NO: 62, HCDR2 of SEQ ID NO: 101, and HCDR3 of SEQ ID NO: 69, a LCDR1 of SEQ ID NO: 64; a LCDR2 of SEQ ID NO: 59; and a LCDR3 of SEQ ID NO: 70;

a HCDR1 of SEQ ID NO: 71, HCDR2 of SEQ ID NO: 72, and HCDR3 of SEQ ID NO: 73, a LCDR1 of SEQ ID NO: 74; a LCDR2 of SEQ ID NO: 59; and a LCDR3 of SEQ ID NO: 75;

a HCDR1 of SEQ ID NO: 76, HCDR2 of SEQ ID NO: 77, and HCDR3 of SEQ ID NO: 78, a LCDR1 of SGGSGSYGYYG SEQ ID NO: 147; a LCDR2 of SEQ ID NO: 59; and a LCDR3 of SEQ ID NO: 79;

a HCDR1 of SEQ ID NO: 80, HCDR2 of SEQ ID NO: 81, and HCDR3 of SEQ ID NO: 82, a LCDR1 of SEQ ID NO: 83; a LCDR2 of SEQ ID NO: 84; and a LCDR3 of SEQ ID NO: 85;

a HCDR1 of SEQ ID NO: 62, HCDR2 of SEQ ID NO: 86, and HCDR3 of SEQ ID NO: 57, a LCDR1 of SEQ ID NO: 87; a LCDR2 of SEQ ID NO: 88; and a LCDR3 of SEQ ID NO: 89;

a HCDR1 of SEQ ID NO: 90, HCDR2 of SEQ ID NO: 91, and HCDR3 of SEQ ID NO: 92, a LCDR1 of SEQ ID NO: 93; a LCDR2 of SEQ ID NO: 88 and a LCDR3 of SEQ ID NO: 94;

a HCDR1 of SEQ ID NO: 95, HCDR2 of SEQ ID NO: 96, and HCDR3 of SEQ ID NO: 97, a LCDR1 of SEQ ID NO: 98; a LCDR2 of SEQ ID NO: 99; and a LCDR3 of SEQ ID NO: 100;

a HCDR1 of SEQ ID NO: 62, HCDR2 of SEQ ID NO: 101, and HCDR3 of SEQ ID NO: 57, a LCDR1 of SEQ ID NO: 58; a LCDR2 of SEQ ID NO: 59; and a LCDR3 of SEQ ID NO: 60; or

a HCDR1 of SEQ ID NO: 62, HCDR2 of SEQ ID NO: 102, and HCDR3 of SEQ ID NO: 57, a LCDR1 of SEQ ID NO: 87; a LCDR2 of SEQ ID NO: 88; and a LCDR3 of SEQ ID NO: 89.

2. A nucleic acid molecule encoding an antibody of claim 1 .

3. A pharmaceutical composition comprising the antibody of claim 1 , or a nucleic acid molecule encoding the same.

4. The antibody of claim 1 , wherein the antibody comprises a HCDR1 of SEQ ID NO: 53, a HCDR2 of SEQ ID NO: 54, a HCDR3 of SEQ ID NO: 33, a LCDR1 of SEQ ID NO: 50; a LCDR2 of SEQ ID NO: 51; and a LCDR3 of SEQ ID NO: 52.

5. The antibody of claim 1 , wherein the antibody comprises:

a) a light chain variable region having at least 90% identity to the amino acid sequence of SEQ ID NO: 19, the light chain variable region comprising:

i. a light chain CDR1 having the amino acid sequence of SEQ ID NO: 50;

ii. a light chain CDR2 having the amino acid sequence of SEQ ID NO: 51;

iii. a light chain CDR3 having the amino acid sequence of SEQ ID NO: 52; and

b) a heavy chain variable region having at least 90% identity to the amino acid sequence of SEQ ID NO: 18, the heavy chain variable region comprising:

i. a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 53;

ii. a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 54;

iii. a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 33.

6. The antibody of claim 5 , wherein the light chain variable region has at least 95% identity to the amino acid sequence of SEQ ID NO: 19, and the heavy chain variable region has at least 95% identity to the amino acid sequence of SEQ ID NO: 20.

7. The antibody of claim 1 , wherein the antibody comprises a light chain variable region having at least 90% identity to the amino acid sequence of SEQ ID NO: 19, the light chain variable region comprising:

i. a light chain CDR1 having the amino acid sequence of SEQ ID NO: 50;

ii. a light chain CDR2 having the amino acid sequence of SEQ ID NO: 51; and

iii. a light chain CDR3 having the amino acid sequence of SEQ ID NO: 52.

8. The antibody of claim 7 , wherein the light chain variable region has at least 95% identity to the amino acid sequence of SEQ ID NO: 19.

9. The antibody of claim 1 , wherein the antibody comprises a HCDR1 of SEQ ID NO:

62, a HCDR2 of SEQ ID NO: 125, a HCDR3 of SEQ ID NO: 69, a LCDR1 of SEQ ID NO: 58; a LCDR2 of SEQ ID NO: 68; and a LCDR3 of SEQ ID NO: 60.

10. The antibody of claim 1 , wherein the antibody comprises a HCDR1 of SEQ ID NO:

62, a HCDR2 of SEQ ID NO: 125, a HCDR3 of SEQ ID NO: 67, a LCDR1 of SEQ ID NO: 64; a LCDR2 of SEQ ID NO: 59; and a LCDR3 of SEQ ID NO: 60.

11. The antibody of claim 1 , wherein the antibody comprises:

a) a light chain variable region having at least 90% identity to the amino acid sequence of SEQ ID NO: 118, the light chain variable region comprising:

i. a light chain CDR1 having the amino acid sequence of SEQ ID NO: 58;

ii. a light chain CDR2 having the amino acid sequence of SEQ ID NO: 68;

iii. a light chain CDR3 having the amino acid sequence of SEQ ID NO: 60, and

b) a heavy chain variable region having at least 90% identity to the amino acid sequence of SEQ ID NO: 117, the heavy chain variable region comprising:

i. a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 62;

ii. a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 125;

iii. a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 69.

12. The antibody of claim 11 , wherein the light chain variable region has at least 95% identity to the amino acid sequence of SEQ ID NO: 118, and the heavy chain variable region has at least 95% identity to the amino acid sequence of SEQ ID NO: 117.

13. The antibody of claim 1 , wherein the antibody comprises:

a) a light chain variable region having at least 90% identity to the amino acid sequence of SEQ ID NO: 112, the light chain variable region comprising:

i. a light chain CDR1 having the amino acid sequence of SEQ ID NO: 64;

ii. a light chain CDR2 having the amino acid sequence of SEQ ID NO: 59;

iii. a light chain CDR3 having the amino acid sequence of SEQ ID NO: 60, and

b) a heavy chain variable region having at least 90% identity to the amino acid sequence of SEQ ID NO: 111, the heavy chain variable region comprising:

i. a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 62;

ii. a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 125;

iii. a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 67.

14. The antibody of claim 13 , wherein the light chain variable region has at least 95% identity to the amino acid sequence of SEQ ID NO: 112, and the heavy chain variable region has at least 95% identity to the amino acid sequence of SEQ ID NO: 111.

15. The antibody of claim 1 , wherein the antibody comprises a HCDR1 of SEQ ID NO:

62, a HCDR2 of SEQ ID NO: 125, a HCDR3 of SEQ ID NO: 66, a LCDR1 of SEQ ID NO: 64; a LCDR2 of SEQ ID NO: 59; and a LCDR3 of SEQ ID NO: 60.

16. The antibody of claim 1 , wherein the antibody comprises:

a) a light chain variable region having at least 90% identity to the amino acid sequence of SEQ ID NO: 110, the light chain variable region comprising:

i. a light chain CDR1 having the amino acid sequence of SEQ ID NO: 64;

ii. a light chain CDR2 having the amino acid sequence of SEQ ID NO: 59;

iii. a light chain CDR3 having the amino acid sequence of SEQ ID NO: 60, and

b) a heavy chain variable region having at least 90% identity to the amino acid sequence of SEQ ID NO: 109, the heavy chain variable region comprising:

i. a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 62;

ii. a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 125;

iii. a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 66.

17. The antibody of claim 16 , wherein the light chain variable region has at least 95% identity to the amino acid sequence of SEQ ID NO: 110, and the heavy chain variable region has at least 95% identity to the amino acid sequence of SEQ ID NO: 109.

18. The antibody of claim 1 , wherein the antibody comprises a light chain variable region having at least 90% identity to the amino acid sequence of SEQ ID NO: 110, the light chain variable region comprising:

i. a light chain CDR1 having the amino acid sequence of SEQ ID NO: 64;

ii. a light chain CDR2 having the amino acid sequence of SEQ ID NO: 59;

iii. a light chain CDR3 having the amino acid sequence of SEQ ID NO: 60.

19. The antibody of claim 18 , wherein the light chain variable region has at least 95% identity to the amino acid sequence of SEQ ID NO: 110.

20. The antibody of claim 1 , wherein the antibody comprises a HCDR1 of SEQ ID NO: 62, a HCDR2 of SEQ ID NO: 125, a HCDR3 of SEQ ID NO: 65, a LCDR1 of SEQ ID NO: 64; a LCDR2 of SEQ ID NO: 59; and a LCDR3 of SEQ ID NO: 60.

21. The antibody of claim 1 , wherein the antibody comprises:

a) a light chain variable region having at least 90% identity to the amino acid sequence of SEQ ID NO: 108, the light chain variable region comprising:

i. a light chain CDR1 having the amino acid sequence of SEQ ID NO: 64;

ii. a light chain CDR2 having the amino acid sequence of SEQ ID NO: 59;

iii. a light chain CDR3 having the amino acid sequence of SEQ ID NO: 60, and

b) a heavy chain variable region having at least 90% identity to the amino acid sequence of SEQ ID NO: 107, the heavy chain variable region comprising:

i. a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 62;

ii. a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 125;

iii. a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 65.

22. The antibody of claim 21 , wherein the light chain variable region has at least 95% identity to the amino acid sequence of SEQ ID NO: 107, and the heavy chain variable region has at least 95% identity to the amino acid sequence of SEQ ID NO: 108.

23. The antibody of claim 1 , wherein the antibody comprises a light chain variable region having at least 90% identity to the amino acid sequence of SEQ ID NO: 108, the light chain variable region comprising:

i. a light chain CDR1 having the amino acid sequence of SEQ ID NO: 64;

ii. a light chain CDR2 having the amino acid sequence of SEQ ID NO: 59; and,

iii. a light chain CDR3 having the amino acid sequence of SEQ ID NO: 60.

24. The antibody of claim 23 , wherein the light chain variable region has at least 95% identity to the amino acid sequence of SEQ ID NO: 108.

25. A cell comprising the nucleic acid molecule of claim 2 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 2, 2021
From: CHAMBERS, ROSS; RUCKER, JOSEPH; CHARPENTIER, THOMAS; STAFFORD, LEWIS; SCRENCI, BRAD; BARNES, TREVOR; DORANZ, BENJAMIN
To: INTEGRAL MOLECULAR, INC
Reel/Frame 056065/0708 →
Continuity (2)
Provisional Application 62806048 · Feb 15, 2019
Related Publication 20200262915A1 · Aug 20, 2020